MCID: SLV002
MIFTS: 62

Salivary Gland Cancer

Categories: Rare diseases, Cancer diseases, Endocrine diseases, Oral diseases

Aliases & Classifications for Salivary Gland Cancer

MalaCards integrated aliases for Salivary Gland Cancer:

Name: Salivary Gland Cancer 12 36 51 40 14
Malignant Neoplasm of Salivary Gland 12 69
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Salivary Gland Neoplasms 69
Salivary Gland Neoplasm 28

Classifications:



External Ids:

Disease Ontology 12 DOID:8850
ICD10 32 C08
ICD9CM 34 142.8
SNOMED-CT 64 187648003
KEGG 36 H01508

Summaries for Salivary Gland Cancer

MedlinePlus : 40 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Salivary Gland Cancer, also known as malignant neoplasm of salivary gland, is related to pleomorphic adenoma and mucoepidermoid carcinoma, and has symptoms including snoring and halitosis. An important gene associated with Salivary Gland Cancer is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Notch signaling pathway and GPCR Pathway. The drugs Paclitaxel and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the salivary gl, salivary gland and lung, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

Related Diseases for Salivary Gland Cancer

Diseases in the Salivary Gland Cancer family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 pleomorphic adenoma 31.6 ERBB2 SERPINB5 TP63
2 mucoepidermoid carcinoma 29.7 AREG CRTC1 EGFR ERBB2 MAML2 TP63
3 oral cancer 29.7 CASP3 EGFR MMP2 MMP9
4 hidradenoma 29.5 AKT1 CRTC1 MAML2
5 breast cancer 27.5 AKT1 AREG BIRC5 CASP3 EGFR ERBB2
6 salivary gland cancer, adult 12.4
7 salivary gland cancer, childhood 12.1
8 brooke-spiegler syndrome 11.1
9 sublingual gland cancer 11.0
10 parotid gland cancer 11.0
11 breast intraductal proliferative lesion 10.5 EGFR ERBB2
12 cowden syndrome 1 10.4 EGFR PTEN
13 intracystic papillary adenoma 10.4 EGFR ERBB2
14 extracranial arteriovenous malformation 10.4 MMP2 MMP9
15 giant cell glioblastoma 10.4 EGFR PPARG PTEN
16 tumor suppressor gene on chromosome 11 10.4 EGFR ERBB2 PTEN
17 malignant peritoneal mesothelioma 10.4 BIRC5 EGFR
18 malignant pleural mesothelioma 10.4 BIRC5 EGFR MET
19 progesterone-receptor negative breast cancer 10.4 EGFR ERBB2
20 serous cystadenocarcinoma 10.3 AKT1 BIRC5 MMP2
21 breast scirrhous carcinoma 10.3 EGFR ERBB2
22 differentiated thyroid carcinoma 10.3 EGFR MET PPARG
23 estrogen-receptor positive breast cancer 10.3 AKT1 EGFR ERBB2
24 ductal carcinoma in situ 10.3 AKT1 EGFR ERBB2
25 primary effusion lymphoma 10.3 AKT1 CASP3 STAT3
26 endometrial adenocarcinoma 10.3 EGFR ERBB2 PTEN
27 villous adenocarcinoma 10.3 EGFR MMP2 MMP9
28 lentigo maligna melanoma 10.3 MMP2 MMP9
29 grade iii astrocytoma 10.3 EGFR MMP2 PTEN
30 vulvar intraepithelial neoplasia 10.3 BIRC5 MMP2
31 helicobacter pylori infection 10.3 CASP3 EGFR MET
32 adult astrocytic tumour 10.2 MMP7 MMP9 PTEN
33 breast ductal carcinoma 10.2 EGFR ERBB2 MET
34 thyroid cancer, nonmedullary, 1 10.2 MET PPARG PTEN STAT3
35 kidney cancer 10.2 AKT1 EGFR MET PTEN
36 breast adenocarcinoma 10.2 EGFR ERBB2 MMP9
37 hepatoblastoma 10.2 BIRC5 CASP3 MET
38 focal myositis 10.2 MMP2 MMP7 MMP9
39 spastic entropion 10.2 MMP2 MMP7 MMP9
40 senile ectropion 10.2 MMP2 MMP7 MMP9
41 light chain deposition disease 10.2 MMP2 MMP7 MMP9
42 apical myocardial infarction 10.2 AKT1 STAT3
43 tongue squamous cell carcinoma 10.2 CASP3 MMP2 MMP9
44 gallbladder cancer 10.1 AKT1 EGFR ERBB2 MMP2
45 skin melanoma 10.1 CASP3 MMP2 MMP9
46 varicose veins 10.1 MMP2 MMP7 MMP9
47 pancreas adenocarcinoma 10.1 AKT1 AREG EGFR
48 hidradenocarcinoma 10.1 EGFR ERBB2 TP63
49 gastric adenocarcinoma 10.1 CASP3 ERBB2 MET SERPINB5
50 glioblastoma 10.0 AKT1 EGFR ERBB2 MET PTEN

Graphical network of the top 20 diseases related to Salivary Gland Cancer:



Diseases related to Salivary Gland Cancer

Symptoms & Phenotypes for Salivary Gland Cancer

UMLS symptoms related to Salivary Gland Cancer:


snoring, halitosis

GenomeRNAi Phenotypes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.26 CASP3 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 9.26 EGFR
3 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT1 EGFR ERBB2 MET

MGI Mouse Phenotypes related to Salivary Gland Cancer:

43 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.52 TSC22D1 TP63 ERBB2 EGFR AKT1 CASP3
2 growth/size/body region MP:0005378 10.51 TP63 CRTC1 ERBB2 EGFR AKT1 CASP3
3 cellular MP:0005384 10.49 TP63 STAT3 ERBB2 EGFR BIRC5 AKT1
4 homeostasis/metabolism MP:0005376 10.46 TP63 STAT3 CRTC1 ERBB2 EGFR AREG
5 immune system MP:0005387 10.45 TP63 CRTC1 EGFR BIRC5 AKT1 CASP3
6 hematopoietic system MP:0005397 10.44 TSC22D1 CRTC1 EGFR AREG BIRC5 AKT1
7 endocrine/exocrine gland MP:0005379 10.43 TP63 CRTC1 ERBB2 EGFR BIRC5 AKT1
8 mortality/aging MP:0010768 10.42 TP63 STAT3 ERBB2 EGFR AREG BIRC5
9 behavior/neurological MP:0005386 10.4 TP63 STAT3 CRTC1 ERBB2 CASP3 AKT1
10 digestive/alimentary MP:0005381 10.38 TP63 ERBB2 EGFR CASP3 AREG ISL1
11 embryo MP:0005380 10.37 TP63 STAT3 ERBB2 EGFR BIRC5 AKT1
12 muscle MP:0005369 10.29 TP63 ERBB2 EGFR AKT1 CASP3 ISL1
13 integument MP:0010771 10.28 TP63 STAT3 ERBB2 EGFR CASP3 AREG
14 neoplasm MP:0002006 10.27 TP63 ERBB2 EGFR ID1 AKT1 MET
15 craniofacial MP:0005382 10.21 TP63 STAT3 ERBB2 EGFR CASP3 MET
16 nervous system MP:0003631 10.21 STAT3 EGFR ERBB2 CASP3 AKT1 ISL1
17 adipose tissue MP:0005375 10.17 STAT3 EGFR CRTC1 AKT1 PTEN PPARG
18 normal MP:0002873 10.15 TP63 STAT3 ERBB2 EGFR BIRC5 AKT1
19 limbs/digits/tail MP:0005371 10.07 TP63 EGFR ERBB2 ISL1 MET MMP9
20 reproductive system MP:0005389 10.07 TP63 STAT3 CRTC1 ERBB2 EGFR AREG
21 renal/urinary system MP:0005367 10.06 TP63 STAT3 TSC22D1 EGFR CASP3 MET
22 liver/biliary system MP:0005370 10.05 STAT3 EGFR AKT1 ID1 MET PTEN
23 no phenotypic analysis MP:0003012 10.01 TP63 EGFR CASP3 ISL1 ID1 MET
24 respiratory system MP:0005388 9.9 TP63 STAT3 ERBB2 EGFR AKT1 CASP3
25 skeleton MP:0005390 9.73 TP63 STAT3 ERBB2 EGFR AKT1 CASP3
26 vision/eye MP:0005391 9.44 TP63 EGFR CASP3 AREG ISL1 ID1

Drugs & Therapeutics for Salivary Gland Cancer

Drugs for Salivary Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
2
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
6
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
7
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
8
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
11
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
12
Iodine Approved, Investigational Phase 3 7553-56-2 807
13
leucovorin Approved, Nutraceutical Phase 3,Phase 1 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
16 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
17 Analgesics Phase 3,Phase 2
18 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
19 Neurotransmitter Agents Phase 3,Phase 2
20 Dermatologic Agents Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 3,Phase 2
22 Pharmaceutical Solutions Phase 3
23 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
24 Antimetabolites Phase 3,Phase 1,Phase 2
25 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
26 Antimitotic Agents Phase 3,Phase 1,Phase 2
27 Liver Extracts Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
29 Autonomic Agents Phase 3,Phase 2
30 Antirheumatic Agents Phase 3,Phase 2
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Central Nervous System Depressants Phase 3
33 Adjuvants, Anesthesia Phase 3
34 Mitogens Phase 3,Phase 2,Phase 1
35 Folic Acid Antagonists Phase 3,Phase 1
36 Cholinergic Agents Phase 3,Phase 2
37 Narcotics Phase 3
38 Histamine Antagonists Phase 3
39 Analgesics, Opioid Phase 3
40 Anesthetics Phase 3
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1
42 Anesthetics, General Phase 3
43 Vitamin B Complex Phase 3,Phase 2,Phase 1
44 Anesthetics, Intravenous Phase 3
45 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
47 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
48 Endothelial Growth Factors Phase 3,Phase 1
49 Antidepressive Agents Phase 3
50 Antidepressive Agents, Tricyclic Phase 3

Interventional clinical trials:

(show top 50) (show all 179)

# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
2 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
3 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
7 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
8 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
9 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
10 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
11 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Recruiting NCT02048254 Phase 3
12 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
13 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
14 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
15 Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck Unknown status NCT02558387 Phase 2 BIBF1120
16 Activity of Sorafenib in Salivary Gland Cancer Unknown status NCT01703455 Phase 2 Sorafenib
17 CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC Unknown status NCT01154270 Phase 2
18 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
19 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
20 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
21 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
22 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Unknown status NCT00052611 Phase 2 celecoxib
23 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
24 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2 Gefitinib
25 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Completed NCT01613768 Phase 2 eribulin mesylate
26 A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Completed NCT01488838 Phase 2 Cisplatin: 40 mg/m2 weekly during radiation
27 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
28 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
29 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
30 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
31 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
32 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
33 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
34 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
35 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
36 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
37 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
38 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
39 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
40 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
41 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
42 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
43 Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
44 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
45 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
46 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
47 EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer Completed NCT00049140 Phase 2 EF5
48 Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy Completed NCT00559156 Phase 2 cisplatin
49 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
50 Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer Completed NCT00003264 Phase 2 cisplatin;gemcitabine hydrochloride

Search NIH Clinical Center for Salivary Gland Cancer

Genetic Tests for Salivary Gland Cancer

Genetic tests related to Salivary Gland Cancer:

# Genetic test Affiliating Genes
1 Salivary Gland Neoplasm 28

Anatomical Context for Salivary Gland Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Cancer:

18
The Salivary Gl

MalaCards organs/tissues related to Salivary Gland Cancer:

38
Salivary Gland, Lung, Testes, Brain, Liver, Thyroid, Kidney

Publications for Salivary Gland Cancer

Articles related to Salivary Gland Cancer:

(show top 50) (show all 131)
# Title Authors Year
1
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. ( 29044862 )
2018
2
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). ( 28102887 )
2017
3
A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. ( 28133481 )
2017
4
Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study. ( 28881386 )
2017
5
Androgen Receptor Signaling in Salivary Gland Cancer. ( 28208703 )
2017
6
Immunohistochemical and molecular profile of salivary gland cancer in children. ( 28139061 )
2017
7
The rising incidence of major salivary gland cancer in the United States. ( 28346649 )
2017
8
Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. ( 28401485 )
2017
9
Nomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study. ( 28160551 )
2017
10
Develop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancer. ( 28819427 )
2017
11
Effective nasal mask ventilation of a difficult airway in a patient with advanced salivary gland cancer. ( 28494881 )
2017
12
Unmet needs for patients with salivary gland cancer. ( 27377424 )
2016
13
(A+)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. ( 27670669 )
2016
14
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. ( 28006087 )
2016
15
Targeting ID2 expression triggers a more differentiated phenotype and reduces aggressiveness in human salivary gland cancer cells. ( 27364596 )
2016
16
Cytomegalovirus induces Interleukin-6 mediated inflammatory response in salivary gland cancer. ( 28039719 )
2016
17
ID1 Controls Aggressiveness of Salivary Gland Cancer Cells via Crosstalk of IGF and AKT Pathways. ( 27466488 )
2016
18
The MMP-2 and MMP-9 promoter polymorphisms and susceptibility to salivary gland cancer. ( 27569079 )
2016
19
Incidence and risk factors of late recurrence in patients with salivary gland cancer. ( 27960047 )
2016
20
High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. ( 26841273 )
2016
21
Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. ( 26661925 )
2015
22
Outcomes and prognostic factors in modern era management of major salivary gland cancer. ( 26033470 )
2015
23
An epidemiological evaluation of salivary gland cancer in the Netherlands (1989-2010). ( 25454260 )
2015
24
Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers. ( 26252941 )
2015
25
Increased risk of salivary gland cancer among women with a previous cancer diagnosis. ( 25581457 )
2015
26
Convallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia-1. ( 25914292 )
2015
27
The Impact of Demographic and Socioeconomic Factors on Major Salivary Gland Cancer Survival. ( 24647644 )
2014
28
Familial predisposition for salivary gland cancer in Finland. ( 24701124 )
2014
29
Overview of major salivary gland cancer surgery in Ontario (2003A?2010). ( 25492404 )
2014
30
Salivary gland cancer risk and BRCA gene mutations may be linked, study finds. ( 25577819 )
2014
31
Retracted: the oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. ( 25610927 )
2014
32
Salivary Gland Cancer in BRCA-Positive Families : A Retrospective Review. ( 25257187 )
2014
33
Racial and Ethnic Disparities in Salivary Gland Cancer Survival. ( 24744112 )
2014
34
Salivary gland cancer stem cells. ( 23810400 )
2013
35
Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. ( 23517130 )
2013
36
Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo. ( 24398788 )
2013
37
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. ( 23242174 )
2013
38
Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. ( 22836059 )
2013
39
Salivary gland cancer: an update on present and emerging therapies. ( 23714518 )
2013
40
Expression and function of CXCR4 in human salivary gland cancers. ( 22847686 )
2013
41
The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation. ( 23608756 )
2013
42
The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. ( 23611358 )
2013
43
Predictors of cervical lymph node metastasis in salivary gland cancer. ( 23780687 )
2013
44
The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. ( 22445095 )
2012
45
Prognostic significance of RB1-inducible coiled-coil 1 in salivary gland cancers. ( 21717524 )
2012
46
Paediatric salivary gland cancer in Finland. ( 22721526 )
2012
47
Predictive index for lymph node management of major salivary gland cancer. ( 22539053 )
2012
48
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. ( 22240798 )
2012
49
Recurrent salivary gland cancer. ( 22215326 )
2012
50
EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. ( 22154363 )
2012

Variations for Salivary Gland Cancer

Expression for Salivary Gland Cancer

Search GEO for disease gene expression data for Salivary Gland Cancer.

Pathways for Salivary Gland Cancer

Pathways related to Salivary Gland Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 AKT1 AREG BIRC5 EGFR ERBB2 MET
2
Show member pathways
13.56 AKT1 EGFR ERBB2 MET MMP2 MMP9
3
Show member pathways
13.47 AKT1 AREG CASP3 EGFR ERBB2 MET
4
Show member pathways
13.39 AKT1 BIRC5 CASP3 EGFR ERBB2 MET
5
Show member pathways
13.38 AKT1 CASP3 EGFR MMP2 MMP7 MMP9
6
Show member pathways
13.36 AKT1 AREG CASP3 EGFR ERBB2 MET
7
Show member pathways
13.03 AKT1 CASP3 EGFR MAML2 MET PTEN
8
Show member pathways
12.98 AKT1 BIRC5 CASP3 EGFR ERBB2 MET
9
Show member pathways
12.96 AKT1 EGFR ERBB2 MET PTEN STAT3
10
Show member pathways
12.95 AKT1 EGFR ERBB2 MET PTEN STAT3
11
Show member pathways
12.82 AKT1 EGFR ERBB2 MET PTEN
12
Show member pathways
12.78 AKT1 EGFR ERBB2 MET PTEN
13
Show member pathways
12.76 AKT1 CASP3 ERBB2 MET PTEN STAT3
14
Show member pathways
12.72 AKT1 CASP3 EGFR MMP2 PTEN
15
Show member pathways
12.63 AKT1 EGFR ERBB2 MMP2 MMP9
16
Show member pathways
12.63 AKT1 BIRC5 EGFR ERBB2 MMP2 STAT3
17
Show member pathways
12.61 AKT1 BIRC5 CASP3 MMP9 PTEN STAT3
18
Show member pathways
12.54 AKT1 EGFR ERBB2 MET PTEN
19
Show member pathways
12.53 AKT1 CASP3 ERBB2 PTEN STAT3
20
Show member pathways
12.5 AKT1 AREG CASP3 EGFR ERBB2 STAT3
21
Show member pathways
12.49 AKT1 CASP3 EGFR ERBB2 MET
22
Show member pathways
12.48 AKT1 AREG EGFR ERBB2 MET STAT3
23
Show member pathways
12.45 AKT1 BIRC5 MET PTEN STAT3
24 12.39 CASP3 EGFR ERBB2 MET MMP9 PTEN
25
Show member pathways
12.38 AKT1 CASP3 MMP9 STAT3
26
Show member pathways
12.37 AKT1 EGFR ERBB2 PPARG
27
Show member pathways
12.31 AKT1 CASP3 PPARG STAT3
28
Show member pathways
12.29 AKT1 AREG EGFR PTEN
29
Show member pathways
12.24 AKT1 CASP3 EGFR ERBB2 MET PTEN
30 12.23 AKT1 CASP3 EGFR ERBB2 MET MMP2
31 12.22 AKT1 EGFR ERBB2 PTEN STAT3
32 12.2 AKT1 CASP3 EGFR PTEN
33
Show member pathways
12.2 AKT1 EGFR ERBB2 STAT3
34 12.16 AKT1 CASP3 CRTC1 STAT3
35
Show member pathways
12.16 AKT1 EGFR ERBB2 PTEN STAT3
36 12.14 AKT1 ID1 ISL1 STAT3
37
Show member pathways
12.13 AKT1 EGFR PTEN STAT3
38 12.11 ISL1 MET STAT3 TP63
39
Show member pathways
12.11 AKT1 EGFR ERBB2 STAT3
40
Show member pathways
12.1 AKT1 EGFR ERBB2 MMP2 PTEN STAT3
41 12.09 AKT1 BIRC5 CASP3 EGFR ERBB2 MET
42
Show member pathways
12.07 AKT1 EGFR ERBB2 STAT3
43 12.03 EGFR MET MMP2 PTEN SERPINB5 TP63
44 12 AKT1 BIRC5 MMP2 MMP9 STAT3
45 11.98 AKT1 BIRC5 CASP3 EGFR MMP2 MMP7
46 11.96 AKT1 EGFR ERBB2 STAT3
47 11.96 AKT1 CASP3 MMP2 STAT3
48 11.91 AKT1 EGFR PTEN STAT3
49 11.89 MMP2 MMP7 MMP9 SERPINB5
50 11.86 AKT1 PTEN TP63

GO Terms for Salivary Gland Cancer

Cellular components related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 AKT1 BIRC5 CASP3 CRTC1 ID1 ISL1
2 nucleus GO:0005634 9.86 AKT1 AREG BIRC5 CASP3 CRTC1 EGFR
3 cytoplasm GO:0005737 9.53 AKT1 AREG BIRC5 CASP3 CRTC1 EGFR

Biological processes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.98 AKT1 CASP3 MMP9 PPARG PTEN
2 positive regulation of protein phosphorylation GO:0001934 9.89 AKT1 EGFR ERBB2 MMP9
3 aging GO:0007568 9.88 AKT1 MMP7 PTEN STAT3 TP63
4 heart development GO:0007507 9.85 CASP3 ERBB2 ID1 ISL1 PPARG PTEN
5 cellular response to insulin stimulus GO:0032869 9.84 AKT1 PPARG PTEN
6 positive regulation of cell growth GO:0030307 9.84 AKT1 EGFR ERBB2
7 extracellular matrix disassembly GO:0022617 9.83 MMP2 MMP7 MMP9
8 cellular response to mechanical stimulus GO:0071260 9.83 AKT1 EGFR MMP7
9 cellular response to organic cyclic compound GO:0071407 9.81 AKT1 CASP3 STAT3
10 collagen catabolic process GO:0030574 9.81 MMP2 MMP7 MMP9
11 positive regulation of epithelial cell proliferation GO:0050679 9.8 EGFR ERBB2 ID1
12 epidermal growth factor receptor signaling pathway GO:0007173 9.8 AKT1 AREG EGFR
13 cellular response to growth factor stimulus GO:0071363 9.78 AKT1 EGFR ERBB2
14 learning or memory GO:0007611 9.77 CASP3 EGFR PTEN
15 cell proliferation GO:0008283 9.76 AKT1 AREG EGFR ERBB2 MET PTEN
16 cellular response to nerve growth factor stimulus GO:1990090 9.72 AKT1 ID1 PTEN
17 response to estradiol GO:0032355 9.72 AREG CASP3 EGFR PTEN STAT3
18 cellular response to reactive oxygen species GO:0034614 9.71 AKT1 EGFR MMP9
19 cellular response to epidermal growth factor stimulus GO:0071364 9.71 AKT1 EGFR ERBB2 ID1
20 cellular response to cadmium ion GO:0071276 9.69 AKT1 EGFR MMP9
21 positive regulation of DNA binding GO:0043388 9.67 ISL1 MMP9 PPARG
22 endothelial cell morphogenesis GO:0001886 9.66 ID1 MET
23 cellular response to leptin stimulus GO:0044320 9.65 PTEN STAT3
24 response to organic substance GO:0010033 9.65 AKT1 CASP3 PPARG PTEN STAT3
25 negative regulation of cell size GO:0045792 9.64 AKT1 PTEN
26 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.62 AKT1 EGFR
27 negative regulation of apoptotic process GO:0043066 9.61 AKT1 BIRC5 CASP3 EGFR ID1 MMP9
28 negative regulation of protein homodimerization activity GO:0090074 9.57 ID1 ISL1
29 cellular response to decreased oxygen levels GO:0036294 9.56 AKT1 PTEN
30 response to UV-A GO:0070141 9.52 AKT1 EGFR
31 response to organic cyclic compound GO:0014070 9.17 AREG CASP3 EGFR ID1 PPARG PTEN
32 regulation of transcription, DNA-templated GO:0006355 10.31 BIRC5 CRTC1 ERBB2 ID1 ISL1 MAML2
33 transcription, DNA-templated GO:0006351 10.27 BIRC5 CRTC1 ERBB2 ID1 ISL1 MAML2
34 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 AKT1 CRTC1 EGFR ISL1 MAML2 MET
35 positive regulation of cell proliferation GO:0008284 10 AKT1 AREG BIRC5 EGFR ISL1 PTEN

Molecular functions related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein dimerization activity GO:0046983 9.73 ERBB2 ID1 STAT3 TSC22D1
2 enzyme binding GO:0019899 9.65 AKT1 BIRC5 EGFR PPARG PTEN
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 EGFR ERBB2 MET
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 EGFR ERBB2 MET
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 EGFR ERBB2
6 protein phosphatase binding GO:0019903 9.35 EGFR ERBB2 MET PPARG STAT3
7 nitric-oxide synthase regulator activity GO:0030235 9.32 AKT1 EGFR
8 identical protein binding GO:0042802 9.32 AKT1 BIRC5 EGFR ERBB2 MET MMP9
9 protein binding GO:0005515 10.13 AKT1 AREG BIRC5 CASP3 CRTC1 EGFR

Sources for Salivary Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....